The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

被引：0
|
作者：
He, Zhiyong
Lin, Jinghui
He, Yueming
Zhang, Jing
Yang, Dongyong
Qiu, Wenbin
Lai, Jinhuo
Chen, Xi
Fang, Wenzheng
Ye, Feng
Xu, Tianwen
Wu, Huita
Qiu, Dongfa
Chen, Wujin
Cai, Lifang
Chen, Shengchi
Lin, Qunying
Lin, Li
机构：
[1] Fujian Canc Hosp, Fuzhou, Peoples R China
[2] Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China
[3] Fujian Med Univ, Hosp Quanzhou Affiliated 1, Quanzhou, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Quanzhou, Peoples R China
[5] Fuding Hosp Fujian Prov, Fuding, Peoples R China
[6] Fujian Med Univ, Union Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[7] Fujian Med Univ, 900 Hosp, Joint Logist Team, Clin Med Coll, Fuzhou, Peoples R China
[8] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[9] Fujian Med Coll, Affiliated Hosp 2, Quanzhou, Peoples R China
[10] Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen, Peoples R China
[11] Fujian Med Univ, Sanming Hosp 1, Sanming, Peoples R China
[12] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[13] Fujian Med Univ, Affiliated Hosp, Putian City Hosp 1, Putian City, Peoples R China
[14] First Hosp Nanping, Nanping, Peoples R China
[15] Putian Univ, Affiliated Hosp, Putian, Peoples R China
[16] FuJian Med Univ, Zhangzhou Affiliated Hosp, Zhangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9030
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
    Ni, Yang
    Ye, Xin
    Yang, Xia
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    Wei, Zhigang
    Meng, Min
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (01) : 197 - 203
  • [22] Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
    Yang Ni
    Xin Ye
    Xia Yang
    Guanghui Huang
    Wenhong Li
    Jiao Wang
    Xiaoying Han
    Zhigang Wei
    Min Meng
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 197 - 203
  • [23] Clinical efficacy and safety of apatinib combined with EGFR-TKIs in advanced non-small cell lung cancer with EGFR-TKIs resistance
    Tian, Ruifen
    Guo, Yi
    Zhang, Xia
    Zhang, Xing
    Guo, Wei
    Zhu, Haibo
    Xu, Junjun
    Shen, Fangfang
    Song, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance
    Ricciuti, Biagio
    Mecca, Carmen
    Cenci, Matteo
    Leonardi, Giulia Costanza
    Perrone, Lorenzo
    Mencaroni, Clelia
    Crino, Lucio
    Grignani, Francesco
    Baglivo, Sara
    Chiari, Rita
    Sidoni, Angelo
    Paglialunga, Luca
    Curra, Maria Francesca
    Murano, Emanuele
    Minotti, Vincenzo
    Metro, Giulio
    ECANCERMEDICALSCIENCE, 2015, 9
  • [25] Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
    Si-Yang Maggie Liu
    Cunte Chen
    Yi-Kai Zhang
    Wen-Zhao Zhong
    Yi-Long Wu
    Si-Yang Liu
    Yangqiu Li
    Biomarker Research, 11
  • [26] Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
    Liu, Si-Yang Maggie
    Chen, Cunte
    Zhang, Yi-Kai
    Zhong, Wen-Zhao
    Wu, Yi-Long
    Liu, Si-Yang
    Li, Yangqiu
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [27] Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
    Zhang, Minghui
    Liu, Mingyang
    Wang, Yan
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1293 - E1295
  • [28] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [29] Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Ma, Jie-Tao
    Guo, Yi-Jia
    Song, Jun
    Sun, Li
    Zhang, Shu-Ling
    Huang, Le-Tian
    Jing, Wei
    Zhao, Jian-Zhu
    Han, Cheng-Bo
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [30] Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer
    Lei, Si-Yu
    Xu, Hai-Yan
    Li, Hong-Shuai
    Yang, Ya-Ning
    Xu, Fei
    Li, Jun-Ling
    Wang, Zhi-Jie
    Xing, Pu-Yuan
    Hao, Xue-Zhi
    Wang, Yan
    THORACIC CANCER, 2023, 14 (24) : 2327 - 2337
12345